Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sukaina Virji

Sukaina has been reporting on all aspects of the pharmaceutical and biotechnology space since 2000. In her role as News Editor, she is tasked with ensuring Scrip Intelligence continues to provide the business critical information that its subscribers rely on. Sukaina's prior positions include Editor of the newsletter BioVenture View and the magazine BioPeople. She has a PhD in biochemistry and molecular biology from University College London. Based in the UK, Sukaina is often asked to appear on TV and radio to commentate on business and R&D strategy related to the industry.
Advertisement
Set Alert for Articles By Sukaina Virji

Latest From Sukaina Virji

Three CHMP Negative Opinions ‒ But Who Got A Boon?

The European Medicines Agency's advisory committee, the CHMP, unusually issued three negative opinions at its recent monthly meeting. Which companies received an unexpected boon at the news?

Commercial Therapy Areas

Ethiopia's Dr Tedros New WHO Head

The WHO has elected its first African director general, Dr Tedros Adhanom Ghebreyesus of Ethiopia. He begins his five-year term on July 1, succeeding Dr Margaret Chan of China who has held the top job for a decade.

Policy & Regulation Appointments

Merck & Co Accused Of Anti-Competitive Biosimilar Pricing

The UK's anti-competition authority has accused Merck & Co of anti-competitive behavior in its UK pricing strategy for its infliximab product Remicade.

Commercial Biosimilars

Merck Expands Aduro Collaboration In Keytruda Tie-Up

Aduro Biotech's scientists have a long association with Merck & Co's Keytruda, and things have come full circle as the small biotech's lead anticancer shows promise in combination with the high-profile checkpoint inhibitor.

Research & Development ImmunoOncology

Merck Develops 'New And Improved' CRISPR

Merck of Germany has developed a new genome editing tool that it believes improves on the popular, but IP battle-worn, CRISPR technology. How this will affect the existing IP landscape is as yet unknown.

Research & Development Intellectual Property

Humira's Formulation Patent Loss Boosts Biosimilar Manufacturers

Analysts' views on what the Humira formulation patent loss this week could mean for the launch timing of a biosimilar to AbbVie's main revenue driver vary.

Biosimilars Commercial
See All
Advertisement
UsernamePublicRestriction

Register